Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin

Hélène Gilson, Olivier Schakman, Stéphanie Kalista, Pascale Lause, Kunihiro Tsuchida, Jean Paul Thissen

Research output: Contribution to journalArticle

140 Citations (Scopus)

Abstract

Follistatin (FS) inhibits several members of the TGF-β superfamily, including myostatin (Mstn), a negative regulator of muscle growth. Mstn inhibition by FS represents a potential therapeutic approach of muscle atrophy. The aim of our study was to investigate the mechanisms of the FS-induced muscle hypertrophy. To test the role of satellite cells in the FS effect, we used irradiation to destroy their proliferative capacity. FS overexpression increased the muscle weight by about 37% in control animals, but the increase reached only 20% in irradiated muscle, supporting the role of cell proliferation in the FS-induced hypertrophy. Surprisingly, the muscle hypertrophy caused by FS reached the same magnitude in Mstn-KO as in WT mice, suggesting that Mstn might not be the only ligand of FS involved in the regulation of muscle mass. To assess the role of activin (Act), another FS ligand, in the FS-induced hypertrophy, we electroporated FSI-I, a FS mutant that does not bind Act with high affinity. Whereas FS electroporation increased muscle weight by 32%, the muscle weight gain induced by FSI-I reached only 14%. Furthermore, in Mstn-KO mice, FSI-I overexpression failed to induce hypertrophy, in contrast to FS. Therefore, these results suggest that Act inhibition may contribute to FS-induced hypertrophy. Finally, the role of Act as a regulator of muscle mass was supported by the observation that ActA overexpression induced muscle weight loss (-15%). In conclusion, our results show that satellite cell proliferation and both Mstn and Act inhibition are involved in the FS-induced muscle hypertrophy.

Original languageEnglish
Pages (from-to)E157-E164
JournalAmerican Journal of Physiology - Endocrinology and Metabolism
Volume297
Issue number1
DOIs
Publication statusPublished - 01-07-2009

Fingerprint

Myostatin
Follistatin
Activins
Hypertrophy
Cell Proliferation
Muscles
Ligands
Weights and Measures
Electroporation
Muscular Atrophy

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Physiology
  • Physiology (medical)

Cite this

Gilson, Hélène ; Schakman, Olivier ; Kalista, Stéphanie ; Lause, Pascale ; Tsuchida, Kunihiro ; Thissen, Jean Paul. / Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. In: American Journal of Physiology - Endocrinology and Metabolism. 2009 ; Vol. 297, No. 1. pp. E157-E164.
@article{47b155d7bb5343c09ce0507a3a820d3a,
title = "Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin",
abstract = "Follistatin (FS) inhibits several members of the TGF-β superfamily, including myostatin (Mstn), a negative regulator of muscle growth. Mstn inhibition by FS represents a potential therapeutic approach of muscle atrophy. The aim of our study was to investigate the mechanisms of the FS-induced muscle hypertrophy. To test the role of satellite cells in the FS effect, we used irradiation to destroy their proliferative capacity. FS overexpression increased the muscle weight by about 37{\%} in control animals, but the increase reached only 20{\%} in irradiated muscle, supporting the role of cell proliferation in the FS-induced hypertrophy. Surprisingly, the muscle hypertrophy caused by FS reached the same magnitude in Mstn-KO as in WT mice, suggesting that Mstn might not be the only ligand of FS involved in the regulation of muscle mass. To assess the role of activin (Act), another FS ligand, in the FS-induced hypertrophy, we electroporated FSI-I, a FS mutant that does not bind Act with high affinity. Whereas FS electroporation increased muscle weight by 32{\%}, the muscle weight gain induced by FSI-I reached only 14{\%}. Furthermore, in Mstn-KO mice, FSI-I overexpression failed to induce hypertrophy, in contrast to FS. Therefore, these results suggest that Act inhibition may contribute to FS-induced hypertrophy. Finally, the role of Act as a regulator of muscle mass was supported by the observation that ActA overexpression induced muscle weight loss (-15{\%}). In conclusion, our results show that satellite cell proliferation and both Mstn and Act inhibition are involved in the FS-induced muscle hypertrophy.",
author = "H{\'e}l{\`e}ne Gilson and Olivier Schakman and St{\'e}phanie Kalista and Pascale Lause and Kunihiro Tsuchida and Thissen, {Jean Paul}",
year = "2009",
month = "7",
day = "1",
doi = "10.1152/ajpendo.00193.2009",
language = "English",
volume = "297",
pages = "E157--E164",
journal = "American Journal of Physiology - Endocrinology and Metabolism",
issn = "0193-1849",
publisher = "American Physiological Society",
number = "1",

}

Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin. / Gilson, Hélène; Schakman, Olivier; Kalista, Stéphanie; Lause, Pascale; Tsuchida, Kunihiro; Thissen, Jean Paul.

In: American Journal of Physiology - Endocrinology and Metabolism, Vol. 297, No. 1, 01.07.2009, p. E157-E164.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin

AU - Gilson, Hélène

AU - Schakman, Olivier

AU - Kalista, Stéphanie

AU - Lause, Pascale

AU - Tsuchida, Kunihiro

AU - Thissen, Jean Paul

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Follistatin (FS) inhibits several members of the TGF-β superfamily, including myostatin (Mstn), a negative regulator of muscle growth. Mstn inhibition by FS represents a potential therapeutic approach of muscle atrophy. The aim of our study was to investigate the mechanisms of the FS-induced muscle hypertrophy. To test the role of satellite cells in the FS effect, we used irradiation to destroy their proliferative capacity. FS overexpression increased the muscle weight by about 37% in control animals, but the increase reached only 20% in irradiated muscle, supporting the role of cell proliferation in the FS-induced hypertrophy. Surprisingly, the muscle hypertrophy caused by FS reached the same magnitude in Mstn-KO as in WT mice, suggesting that Mstn might not be the only ligand of FS involved in the regulation of muscle mass. To assess the role of activin (Act), another FS ligand, in the FS-induced hypertrophy, we electroporated FSI-I, a FS mutant that does not bind Act with high affinity. Whereas FS electroporation increased muscle weight by 32%, the muscle weight gain induced by FSI-I reached only 14%. Furthermore, in Mstn-KO mice, FSI-I overexpression failed to induce hypertrophy, in contrast to FS. Therefore, these results suggest that Act inhibition may contribute to FS-induced hypertrophy. Finally, the role of Act as a regulator of muscle mass was supported by the observation that ActA overexpression induced muscle weight loss (-15%). In conclusion, our results show that satellite cell proliferation and both Mstn and Act inhibition are involved in the FS-induced muscle hypertrophy.

AB - Follistatin (FS) inhibits several members of the TGF-β superfamily, including myostatin (Mstn), a negative regulator of muscle growth. Mstn inhibition by FS represents a potential therapeutic approach of muscle atrophy. The aim of our study was to investigate the mechanisms of the FS-induced muscle hypertrophy. To test the role of satellite cells in the FS effect, we used irradiation to destroy their proliferative capacity. FS overexpression increased the muscle weight by about 37% in control animals, but the increase reached only 20% in irradiated muscle, supporting the role of cell proliferation in the FS-induced hypertrophy. Surprisingly, the muscle hypertrophy caused by FS reached the same magnitude in Mstn-KO as in WT mice, suggesting that Mstn might not be the only ligand of FS involved in the regulation of muscle mass. To assess the role of activin (Act), another FS ligand, in the FS-induced hypertrophy, we electroporated FSI-I, a FS mutant that does not bind Act with high affinity. Whereas FS electroporation increased muscle weight by 32%, the muscle weight gain induced by FSI-I reached only 14%. Furthermore, in Mstn-KO mice, FSI-I overexpression failed to induce hypertrophy, in contrast to FS. Therefore, these results suggest that Act inhibition may contribute to FS-induced hypertrophy. Finally, the role of Act as a regulator of muscle mass was supported by the observation that ActA overexpression induced muscle weight loss (-15%). In conclusion, our results show that satellite cell proliferation and both Mstn and Act inhibition are involved in the FS-induced muscle hypertrophy.

UR - http://www.scopus.com/inward/record.url?scp=67650071006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650071006&partnerID=8YFLogxK

U2 - 10.1152/ajpendo.00193.2009

DO - 10.1152/ajpendo.00193.2009

M3 - Article

C2 - 19435857

AN - SCOPUS:67650071006

VL - 297

SP - E157-E164

JO - American Journal of Physiology - Endocrinology and Metabolism

JF - American Journal of Physiology - Endocrinology and Metabolism

SN - 0193-1849

IS - 1

ER -